Prostatis Group’s Teladoc Health TDOC Stock Holding History

Prostatis Group’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,907	Closed	-$210K	–	81
2022 Q1	$210K	Buy	+2,907	New	+$209K	0.17%	79

Other funds holding TDOC

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Prostatis Group's TDOC Position: Q2 2022 in Review

Prostatis Group sold out of Teladoc Health (TDOC) in Q2 2022, closing a stake of 2,907 shares — an estimated $210K sold.

Prostatis Group first reported a position in TDOC in Q1 2022 and held it in 1 quarter. The position peaked at $210K in Q1 2022. 550 funds tracked by Wall St. Rank hold TDOC as of Q2 2022.

Prostatis Group reported no remaining Teladoc Health position as of Q2 2022 after selling out during the quarter.
Prostatis Group sold 2,907 Teladoc Health shares in Q2 2022, an estimated $210K.
Prostatis Group first reported a position in Teladoc Health in Q1 2022 and held it in 1 quarter.
Prostatis Group's Teladoc Health position peaked at $210K in Q1 2022.
550 funds tracked by Wall St. Rank held Teladoc Health as of Q2 2022.

Based on Prostatis Group's 13F filing for Q2 2022, filed 23 Mar 2023.